Arca
Skip to content
Tools
Tools

Gout

Drug research and approvals for gout: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 38 studies of gout are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 2 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 38
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 38 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

12 approved, 8 in phase 3, 14 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Allopurinol, Febuxostat, Colchicine, Pegloticase, Lesinurad, Naproxen, Rasburicase, Cinchophen, Benzbromarone, Sulfinpyrazone, Probenecid, Tisopurine

Canakinumab
Phase 3 Interleukin-1 beta inhibitor
Rilonacept
Phase 3 Interleukin-1 beta inhibitor
Pegadricase
Phase 3 Uric acid oxidative enzyme
SHR-4640
Phase 3 Solute carrier family 22 member 12 inhibitor
Celecoxib
Phase 3 Cyclooxygenase-2 inhibitor
Betamethasone dipropionate
Phase 3 Glucocorticoid receptor agonist
Lansoprazole
Phase 3 Potassium-transporting ATPase inhibitor
Dotinurad
Phase 3 Solute carrier family 22 member 12 inhibitor
Verinurad
Phase 2 Solute carrier family 22 member 12 inhibitor
Ulodesine
Phase 2 Purine nucleoside phosphorylase inhibitor
Anakinra
Phase 2 Interleukin-1 receptor antagonist
Arhalofenate
Phase 2 Peroxisome proliferator-activated receptor gamma modulator
Diacerein
Phase 2 Unknown
Azathioprine
Phase 2 Amidophosphoribosyltransferase inhibitor
Diclofenac
Phase 2 Cyclooxygenase inhibitor
Mycophenolate mofetil
Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Denosumab
Phase 2 Tumor necrosis factor ligand superfamily member 11 inhibitor
Methylprednisolone acetate
Phase 2 Glucocorticoid receptor agonist
Dexamethasone
Phase 2 Glucocorticoid receptor agonist
Apremilast
Phase 2 Phosphodiesterase 4 inhibitor
Bucillamine
Phase 2 Antioxidant
Methotrexate
Phase 1 Dihydrofolate reductase inhibitor
Rituximab
Phase 1 B-lymphocyte antigen CD20 binding agent

How Its Trials Ended

190 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 59 whose ending is known, 73% met their primary endpoint, 5% missed it and 22% stopped early.

  • Completed, result not reported7439%
  • Met its primary endpoint4323%
  • Ongoing3619%
  • Status unknown2111%
  • Stopped: other or unclear53%
  • Missed its primary endpoint32%
  • Stopped: lack of efficacy32%
  • Stopped: enrollment or feasibility21%
  • Stopped: sponsor or business decision21%
  • Stopped: funding11%

Trials Authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Mar 3, 2014A randomized, double-blind, active and placebo-controlled study to evaluate the efficacy and safety of arhalofenate for preventing flares and reducing serum…Arhalofenate (MBX-102)Cymabay Therapeutics IncOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Jul 7, 2022KrystexxaTreatment of chronic gout in adult patients refractory to conventional therapyHorizon Therapeutics Ireland DACApproved
Sep 14, 2010KrystexxaTreatment of chronic gout in adult patients refractory to conventional treatmentHorizon Therapeutics Ireland DACApproved
Jun 6, 2005Polyethylene glycol-modified uricaseTreatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicatedSwedish Orphan Biovitrum ABDesignated

Medicines Authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.